PRESS RELEASE

Companies Complete First Step in Integration of Cue® Cell Processing System and Constellation® Robotic Manufacturing Platform

CAMBRIDGE, UK, January 22, 2026: Cellular Origins announced today they have successfully completed the first phase of their collaboration with Fresenius Kabi designed to help scale the manufacturing of cell and gene therapies using advanced robotics and cell processing technologies.

Cellular Origins is focused on enabling scalable, cost-effective, and efficient robotic manufacture of cell and gene therapies (CGTs). Fresenius Kabi, an Operating Company of Fresenius, is a leading provider of essential medicines and medical technologies.

This milestone marks the completion of the digital and physical integration of Fresenius Kabi’s Cue® Cell Processing System into Cellular Origins’ Constellation® CGT robotic manufacturing platform. Together, the companies have developed a novel integrated approach to robotic-operated cell processing, following the signing of the original agreement on October 16, 2024.

The integration of the Cue and Constellation systems is designed to deliver end-to-end automation. This results in significantly reduced manual intervention. Both Cellular Origins and Fresenius Kabi have now completed studies with human T cells that confirm that the Cue system can reliably execute complex and precise workflows.

“It has been widely known that manufacturing costs and variability are major challenges to the widespread adoption of cell and gene therapies. These challenges have limited broader access to advanced therapies. Reducing manual touchpoints is an important part of supporting more consistent and scalable manufacturing processes,” said Dr Edwin Stone, CEO at Cellular Origins. “Cellular Origins is forming strong relationships with central companies like Fresenius Kabi to enable the CGT industry to robotically automate whilst maintaining its existing processes. Achieving this milestone within 12 months reflects the strong technical alignment between the teams and supports our progress toward future system development, ultimately helping to enable broader patient access to advanced therapies.”

“At Fresenius Kabi we are driving innovation in cell and gene therapy manufacturing by embedding robotic automation into our Cell Therapy Technologies,” said Christian Hauer, President MedTech, Fresenius Kabi. “This milestone demonstrates how automated precision, efficiency, and reliability can improve processes and established workflows, reduce manual labour, and help make advanced therapies more accessible to patients worldwide.” 

Robotics-operated automation of these processes is a critical step towards fully automated, clinically and commercially relevant cell and gene therapy manufacturing. Full automation removes manual labour therefore reducing cost, variability and the potential for human error, while opening the pathway to achieve manufacturing success at commercial scale. It also provides a fully digital chain of custody, enabling the potential to deploy advanced optimisation that could increase productivity and improve the process.

The completion of the first phase of the collaboration has highlighted the level of focus needed to ensure the biological processes are unaffected by automation. Cellular Origins has already developed a suite of tools that allow the application of automation without changing those biological processes.

Following the initial stage, the collaboration will now focus on scaling manufacturing for clinical and commercial manufacturing. The development team will also integrate Cellular Origins’ Constellation into Fresenius Kabi’s wider Cell Therapy Technologies portfolio, including the Lovo® Cell Processing System.

Cellular Origins has prioritised developing and strengthening collaborations with leading suppliers of life science instrumentation and leveraging its flagship Constellation robotic platform. This enables CGT developers and manufacturers to adopt the system into their workflows without having to change or redesign current processes.

About Cellular Origins www.cellularorigins.com 

Cellular Origins is enabling the manufacture of cell therapies at scale through a flexible, factory-led automation platform that adapts to existing processes and facilities. Its Constellation ecosystem unites mobile robotics, and automated sterile welding with proven bioprocess instruments, eliminating the need for therapy redevelopment and providing a dependable route from clinical to commercial manufacture. Designed to flex around any facility and to evolve with advancing therapies, the Constellation platform provides a flexible, future-proof foundation for large scale production and wider ATMP growth. Trusted by market leaders including Cytiva, Fresenius Kabi, Thermo Fisher Scientific and Wilson Wolf, Cellular Origins is building the automation infrastructure required to scale manufacture of 100,000s of doses of transformative therapies reliably and efficiently.

About Fresenius Kabi www.fresenius-kabi.com/us

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to essential medicines and technologies.

In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care.

Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare.

Fresenius Kabi is part of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale.

For more information, please visit www.fresenius-kabi.com/us. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/careers and follow us on LinkedIn and Facebook